FDA approves Tasigna for chronic myeloid leukemia
The US Food and Drug Administration has approved 150 mg Tasigna (nilotinib) capsules as a first-line therapy for patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML). Tasigna is the first drug to be given approval for CML since the FDA approved Gleevec almost a decade ago.
Approval comes thanks to results from the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients) Phase III clinical trial, a randomized, open-label, multicenter trial pitting Tasigna's safety and efficacy profile against that of Gleevec. The data has been published in the New England Journal of Medicine.
Pharmaceutical giant Novartis is the maker of both Gleevec and Tasigna. The company will likely be losing patent protection on Gleevec sometime in 2010 in the US.
Sources:
- Medical News Today
- "Gleevec maker Novartis Meets its Match in India"
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
